We isolated oryctin, a 66-residue peptide, from the hemolymph of the coconut rhinoceros beetle, Oryctes rhinoceros, and cloned its cDNA. Oryctin is dissimilar to any other known peptides in amino-acid sequence, and its function has been unknown. To reveal that function, we determined the solution structure of recombinant 13 C, 15 N-labeled oryctin by heteronuclear NMR spectroscopy. Oryctin exhibits a fold similar to that of Kazal-type serine protease inhibitors, but has a unique additional C-terminal α-helix. We performed protease inhibition assays of oryctin against several bacterial and eukaryotic proteases. Oryctin does inhibit the following serine proteases: α-chymotrypsin, endopeptidase K, subtilisin Carlsberg, and leukocyte elastase, with K i values of 3.9 × 10 -10 M, 6.2 × 10 -10 M, 1.4 × 10 -9 M, and 1.2 × 10 -8 M, respectively. Although the target molecule of oryctin in the beetle hemolymph remains obscure, our results showed that oryctin is a novel single-domain Kazal-type inhibitor and could play a key role in protecting against bacterial infections.
We isolated oryctin, a 66-residue peptide, from the hemolymph of the coconut rhinoceros beetle, Oryctes rhinoceros, and cloned its cDNA. Oryctin is dissimilar to any other known peptides in amino-acid sequence, and its function has been unknown. To reveal that function, we determined the solution structure of recombinant 13 C, 15 N-labeled oryctin by heteronuclear NMR spectroscopy. Oryctin exhibits a fold similar to that of Kazal-type serine protease inhibitors, but has a unique additional C-terminal α-helix. We performed protease inhibition assays of oryctin against several bacterial and eukaryotic proteases. Oryctin does inhibit the following serine proteases: α-chymotrypsin, endopeptidase K, subtilisin Carlsberg, and leukocyte elastase, with K i values of 3.9 × 10 -10 M, 6.2 × 10 -10 M, 1.4 × 10 -9 M, and 1.2 × 10 -8 M, respectively. Although the target molecule of oryctin in the beetle hemolymph remains obscure, our results showed that oryctin is a novel single-domain Kazal-type inhibitor and could play a key role in protecting against bacterial infections.
Eggs and larvae of the coconut rhinoceros beetle, Oryctes rhinoceros, live in compost in warm areas such as Southeast Asia. This beetle has thus developed a self-defense system that includes anti-microbial peptides. Several anti-microbial peptides were isolated from the hemolymph of the beetle: defensin (1), rhinocerosin (2) , and scarabaecin (3) . Oryctin (GenBank Accession Number: BAA36402), a 66-residue peptide with three intramolecular disulfide bonds, was found as a hemolymph peptide of the beetle during a search for antibacterial peptides. The function of oryctin has been unclear, because no other known peptide or protein is sequentially similar to oryctin. We took a structural approach to reveal the function of oryctin. First, we determined the solution structure of recombinant 13 C, 15 N-labeled oryctin by heteronuclear NMR spectroscopy. Next, we searched for proteins that are structurally similar to oryctin in the Protein Data Bank (PDB). The search revealed that oryctin has a fold that is similar in part to that of the turkey ovomucoid third Kazal domain (OMTKY3) † , a serine protease inhibitor. We then performed protease inhibition assays of oryctin and found that oryctin inhibits eukaryotic chymotrypsin-like serine proteases, such as α-chymotrypsin and leukocyte elastase, and bacterial subtilisin-like serine proteases, such as subtilisin Carlsberg and endopeptidase K. Therefore, oryctin is a novel single-domain Kazal-type inhibitor despite its unique amino-acid sequence. Kazal-type serine protease inhibitors usually consist of multiple Kazal domains, each of which has a characteristic disulfide linkage pattern, Cys I -Cys V , Cys II -Cys IV and Cys III -Cys VI , as well as a secondary structure consisting of an α-helix and an antiparallel β-sheet. Here we discuss the structure and function of oryctin by comparing the sequences, the patterns of the disulfide linkages, and the tertiary structures. injection of heat-killed E. coli. The hemolymph was centrifuged at 39,100xg for 50 min at 4°C. The supernatant was heated in boiling water for 10 min and then cooled on ice and centrifuged at 39,100xg for 50 min at 4°C. The supernatant was acidified with 0.1% (v/v) trifluoroacetic acid (TFA) and applied onto a Sep-Pak Vac tC18 column (Waters, Milford, MA) equilibrated with 0.1% (v/v) TFA and eluted with 10, 20, 30, 40, 50 and 100% (v/v) acetonitrile containing 0.1% (v/v) TFA. The 40% (v/v) acetonitrile fraction was applied to a PepRPC column (GE Healthcare, Buckinghamshire, UK) equilibrated with 0.05% (v/v) heptafluorobutanoic acid (HFBA). The adsorbent was eluted with a linear gradient of acetonitrile: 0-20% (v/v) in 5 min, followed by 20-40% (v/v) in 40 min at a flow rate of 0.5 ml/min. The fractions containing oryctin were applied to the same system but using 0.05% (v/v) TFA instead of 0.05% (v/v) HFBA. Peptide sequencing-Peptide sequencing was performed using LF3400 (Beckman Coulter, Fullerton, CA) and Procise cLC492 (ABI, Foster City, CA) protein sequencers. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS)-MALDI-TOF-MS was measured on a Voyager Linear spectrometer (ABI). About 1 pmol of purified oryctin was dissolved in 1 µl of 0.1% (v/v) TFA. The sample solution was then mixed with saturated sinapinic acid solution in 50% (v/v) acetonitrile containing 0.1% (v/v) TFA directly on the target. cDNA cloning-The cDNA encoding oryctin was cloned using the following three-step PCR amplification.
Step 1. Reverse transcriptase-PCR. The fat body was collected 10 h after the injection of heat-killed E. coli. The poly(A) + RNA was purified from the fat body using a Quick Prep mRNA purification kit (GE Healthcare). The first-strand cDNA was synthesized from 1.32 µg of the poly(A) + RNA using a first-strand cDNA synthesis kit (GE Healthcare). Using the first-strand cDNA as a template, RT-PCR was performed using degenerate primers: the sense primer O1F (17-mer), whose sequence was deduced from the amino-acid sequence of Val1-Asp6 [5'-GTNCCNGTNGGN(AT)(CG)NGA-3'] and the antisense primer O1R (20-mer), whose sequence was deduced from the amino-acid sequence of Asn23-Val29 [5'-AC(AGT) .
A 45-cycle step-down protocol was used: denaturation at 94°C for 8 min (first cycle) or 30 s (second and following cycles), annealing at 60°C (initial 5 cycles), 55°C (second 5 cycles), 50°C (third 5 cycles), 45°C (fourth 5 cycles) or 40°C (final 25 cycles) for 30 s, and polymerization at 72°C for 30 s. The resultant 86 bp fragment was subcloned into a TA cloning vector (Invitrogen, Carlsbad, CA). DNA sequencing was performed using an ABI model 373A DNA sequencer with the dye-terminator protocol.
Step 2. 3'-Rapid amplification of cDNA end. 3'-RACE was done using the first-strand cDNA as the template, the antisense NotI adaptor primer 5'-AACTGGAAGAATTCGCGGC-3', and the sense primer O2F (22-mer), whose sequence was derived from the result of Step 1:
A 35-cycle PCR was used: denaturation at 94°C for 8 min (first cycle) or 30 s (second and following cycles), annealing at 50°C for 30 s, and polymerization at 72°C for 30 s. The amplified fragment was subcloned and sequenced as described above.
Step 3. 5'-Rapid amplification of cDNA end. 5'-RACE was done using the 5'-RACE kit (Gibco, Gaithersburg, MD). The first-strand cDNA was synthesized using the antisense primer OGSP1 (16-mer), whose sequence was derived from the result of Step 2: TTATGGACGTGGTGCA. The terminal deoxynucleotidyl transferase reaction was performed on ice for 1 h. The nested PCR was performed using the antisense primer OGSP2 (24-mer), TTTTTGATTGCTTCTTCACACTCG, and the abridged anchor primer. A 40-cycle PCR was used: denaturation at 94°C for 6 min (first cycle) or 1 min (second and following cycles), annealing at 50°C for 30 s, and polymerization at 72°C for 1 min. The amplified fragment was subcloned and sequenced as described above. Determination of disulfide linkages-About 1 µg of oryctin was dissolved in 10 µl of 20 mM sodium bicarbonate (pH 8.5) containing 0.1 µg of lysyl endopeptidase (Wako, Tokyo, Japan) and endoprotease Asp-N (Boehringer Mannheim, Mannheim, Germany) and incubated at 37°C for 4 h. The reaction mixture was applied directly to MALDI-TOF-MS.
α-cyano-4-hydroxycinnamic acid (α-CHCA) was used as the matrix. Gene expression analysis-RT-PCR was carried out as described previously (1) 15 N-edited NOESY-HSQC, and 13 C-edited NOESY-HSQC. The mixing times for the 15 N-edited and 13 C-edited NOESY-HSQC's were 75 and 150 ms. All the acquired data were processed, visualized and analyzed with the programs NMRPipe (4), NMRDraw (4) and Sparky (http://www.cgl.ucsf.edu/home/sparky/), respectively. Dihedral angle restraints-The programs CSI (5) and TALOS (6) were used to predict the regions of α-helix and β-strand based on 13 Structure calculations were performed using CYANA (7). Two-hundred conformers were annealed in 10,000 steps of torsion angle dynamics calculations, of which 20 conformers with the lowest values in the target function were used to represent the solution structure of oryctin. The conformer with the lowest target function was used as the representative structure of oryctin. The tertiary structure was visualized with the programs Molmol (8) and PyMol (http://pymol.sourceforge.net/). The five conformers with the lowest target functions were submitted to the Dali server (9) to search for proteins structurally similar to oryctin.
Protease inhibition assays-α-chymotrypsin, leukocyte elastase, subtilisin Carlsberg, endopeptidase K, trypsin, papain, and thermolysin were purchased from Sigma-Aldrich (St. Louis, MO), V8 protease, pepsin, and lysyl endopeptidase were from Wako Pure Chemical Industries (Osaka, Japan), proline-specific endopeptidase was from Seikagaku Corporation (Tokyo, Japan), and endoproteinases Arg-C and Asp-N were from Roche Diagnostics (Basel, Switzerland). Peptidyl-MCA substrates (MCA  substrates) and MOCAc/Dnp type fluorescence-quenching substrates (MOCAc/Dnp substrates) for the above-mentioned proteases (shown in Table 2 ) were purchased from Peptide Institute (Osaka, Japan). In the case of MCA substrates, the protease activity was measured using fluorescence intensity, where 380 nm and 460 nm were used as the excitation and detection wavelengths, respectively. In the case of MOCAc/Dnp substrates, the protease activity was measured using fluorescence intensity, where 328 nm and 393 nm were used as the excitation and detection wavelengths, respectively. The pH-dependent inhibitory activity was assayed as follows. A reaction mixture containing 3.3 nM protease, 10 nM oryctin, and 66, 100, or 130 µM MCA substrate or 6.6, 10, or 13 µM MOCAc/Dnp substrate in 10 mM Tris-HCl (pH 7.2-9.2) was incubated at 37°C for 10 min, and then HCl was added to stop the reaction. Exceptionally, for a reaction involving pepsin, the pH of the reaction mixture was adjusted to 1.0-3.0 with HCl, and the reaction was stopped by adding 3 M Tris-HCl (pH 8.0). The temperature-dependent inhibitory activity was assayed as follows. A reaction mixture containing 3.3 nM protease, 10 nM oryctin, and 33, 66, 100, or 130 µM MCA substrate or 3.3, 6.6, 10, or 13 µM MOCAc/Dnp substrate in 10 mM Tris-HCl (pH 8.0) was incubated at 10-70°C for 3 min, and then HCl was added to stop the reaction. The mode of protease inhibition and the inhibition constant (K i ) value were determined with a reaction mixture containing 3.3 nM protease, 83, 170, 250, 330, or 500 µM MCA substrate, and 0.83, 1.7, 2.5, 3.3 or 5.0 nM oryctin (for α-chymotrypsin, endopeptidase K, and subtilisin Carlsberg) or 8.3, 17, 25, 33, or 50 nM oryctin (for leukocyte elastase), respectively. The reaction mixtures were incubated at 37°C for 5 min, and then HCl was added to stop the reaction. The acquired data were plotted on Lineweaver-Burk plots. The kinetics parameters (K m 
RESULTS
Peptide isolation, cDNA cloning and primary structure determination-Oryctin was found and isolated during the purification of antibacterial peptides from the hemolymph of the coconut rhinoceros beetle, Oryctes rhinoceros. About 1.0 µg of oryctin was obtained from 1.0 ml of the hemolymph by four steps of reverse-phase HPLC. The N-terminal amino-acid sequence was determined using a protein sequencer, and the oryctin cDNA was cloned by three steps of PCR using fat body mRNA from immunized larvae. The deduced amino-acid sequence from the nucleotide sequence indicated that oryctin contains an 85-amino-acid precursor, and a 66-amino-acid mature peptide is assumed to be produced by cleavage of the signal peptide (Fig. S1 ). There is no sequence similarity between oryctin and any other known peptides or proteins. The MALDI-TOF-MS data indicated that oryctin is a monomeric peptide with three intramolecular disulfide bonds and without any other modifications. The molecular masses (m/z) of detected ions after the digestion with lysyl endopeptidase and endoproteinase Asp-N were 1707.57, 1998.21 and 2808.69, respectively, using MALDI-TOF-MS (Fig. 1) . Thus, we have concluded that three disulfide bonds are formed in oryctin: Cys7-Cys42, Cys12-Cys35 and Cys20-Cys56 (Fig. 1) . Gene expression analysis-Oryctin was constitutively expressed in the fat bodies, hemocytes, midguts and Malpighian tubules of the third instar larvae. Injection of E. coli into the larvae did not affect the expression of oryctin (Fig.  S2) . NMR structural analysis-By using the conventional 3D NMR data, 607 atoms of backbone and sidechain 1 H, 13 C, 15 N were assigned. The 1 H- 15 N HSQC spectrum of oryctin is shown in Fig. 2A . One-hundred percent (57 residues, except proline and the N-terminal residue) of the backbone 1 H, 13 C, 15 N atoms were assigned. The secondary structure regions predicted by both CSI and TALOS were restrained with the backbone dihedral angle (φ and ψ) restraints in the structure calculations (α: Ala36-Gln43 and Gln55-Lys61 Fig. 2B . Tertiary structure-The three-dimensional structure of oryctin was calculated based on 552 NOE-derived distance restraints, 3 disulfide bond restraints (9 distance restraints), 3 hydrogen bond restraints (12 distance restraints), and 79 dihedral angle (38 φ and 41 ψ) restraints. A total of 200 structures were calculated, and the 20 structures with the lowest target functions were selected as an ensemble representing the solution structure of oryctin (Fig. 2C) . The restraints used and the structural statistics for the final structure are summarized in Table 1 . The oryctin molecule consists of a two-stranded antiparallel β-sheet (β1: His19-Leu22; β2: Ile28-Val31) and two α-helices (α1: Gly34-Gln43; α2: His54-Asn62). Three disulfide bonds were formed at Cys7-Cys42, Cys12-Cys35 and Cys20-Cys56. The pairwise RMSDs for backbone and all non-hydrogen atoms were 0.79 ± 0.17 Å and 1.43 ± 0.21 Å, respectively, among the 20 structures excluding five N-and five C-terminal residues. A representative structure with the lowest target function value is shown in Fig. 3A . The central β-sheet is rich in hydrophobic residues (His19, Cys20, Phe21, Leu22, Ile28, Val29, Val30 and Val31). The hydrophobic residues on the β-sheet and on the α-helices (α1: Ala36, Leu37 and Tyr40; α2: Cys56, Ala59 and Asn62) form a hydrophobic cluster and contribute to conformational stabilization. The Cys20-Cys56 disulfide bond is included in the hydrophobic cluster. Structural similarity to the third domain of turkey ovomucoid-A structural similarity search using the Dali server (9) showed that oryctin is structurally similar to the third domain of turkey ovomucoid (OMTKY3) ( Fig. 3B; (Fig. S3A) . Oryctin, consisting of 66 residues, has three intramolecular disulfide bonds (Cys7-Cys42, Cys12-Cys35 and Cys20-Cys56), and OMTKY3, consisting of 51 residues, also has three intramolecular disulfide bonds (Cys8-Cys38, Cys16-Cys35 and Cys24-Cys56). In terms of secondary structure, oryctin has two α-helices and two β strands, whereas OMTKY3 has one α-helix and three β strands. Both oryctin and OMTKY3 possess a backbone fold similar to those of Kazal-type inhibitors: a central α-helix and an antiparallel β-sheet. The structural difference between oryctin and OMTKY3 is largest in the C-terminal regions, where oryctin has an amphipathic α-helix, whereas OMTKY3 has a short β strand. The amino-acid sequence of the reactive-site loop (P4-P3-P2-P1-P1') including (shown in purple in Fig. 3A,B) , suggesting that oryctin also could function as a serine protease inhibitor.
Protease inhibitory activity- Fig. S4 shows the pH-dependent inhibitory activity of oryctin against eukaryotic and bacterial proteases. Oryctin inhibited eukaryotic serine proteases, α-chymotrypsin and leukocyte elastase, and bacterial serine proteases, subtilisin Carlsberg and endopeptidase K, over a pH range of 7.2-9.2, indicating it acts as a serine protease inhibitor in the beetle hemolymph. Fig. 4 shows the temperature-dependent inhibitory activity of oryctin against the above-mentioned four proteases, demonstrating that oryctin has inhibitory activity in a temperature range of 10-70°C against the four proteases in 10 mM Tris-HCl (pH 8.0 (Fig. 6A,B) . In the case of α-chymotrypsin binding (Fig. 6A) , His19, Cys20, Gly33, Gly34, Leu50 and His54 exhibited large chemical shift changes (> 0.06 ppm); Thr13, Val31, His32, Ala36, Lys49, Gly51, Tyr52 and Glu58 exhibited moderate chemical shift changes (0.04-0.06 ppm); and Asp15, Val17, Val29, Val30, Ser38, Glu48, Glu55, Glu57, Ile60, Asn62 and Ala63 exhibited small chemical shift changes (0.02-0.04 ppm). The residues with degenerated or invisible signals are not colored in this figure (Val1, Val3, Asp6, Lys10, Ile28, Cys35 and Lys37), nor are prolines (positions 2, 9, 18, 24, 45, 64 and 66). In the case of leukocyte elastase binding (Fig.  6B) , His19, Leu50, His54, and Glu55 exhibited large chemical shift changes (> 0.06 ppm); Cys20, Val31, Gly33, Gly34, Tyr52 and Cys60 exhibited moderate chemical shift changes (0.04-0.06 ppm); and Cys7, Cys12, Thr13, Met14, Val17, Phe21, Val29, His32, Ala36, Glu48, Lys49, Gly51, Thr53, Glu57 and Ala63 exhibited small chemical shift changes (0.02-0.04 ppm). Degenerated or invisible signals are not colored in this figure (Val1, Val3, Asp6, Lys10, Asp15, Ile28, Cys35, Lys37 and Glu58), nor are prolines (positions 2, 9, 18, 24, 45, 64 and 66). The amino-acid residues whose chemical shifts were perturbed by the addition of α-chymotrypsin and/or leukocyte elastase are mostly common and located in three regions of the sequence (Fig. 6A,B) : (i) the putative reactive site near the N-terminus (residues 13-20 and 12-21 in the cases of α-chymotrypsin and leukocyte elastase binding, respectively), (ii) the central part (residues 29-38 and 29-36), and (iii) the C-terminal part (residues 48-63 in both cases). When these residues are mapped on the oryctin structure, they form a circle around the molecule like a belt (Fig. 6C,D) . Since the similar surface areas of oryctin show chemical shift perturbations through the binding of oryctin to α-chymotrypsin or leukocyte elastase, oryctin should recognize these serine proteases in a very similar manner.
DISCUSSION
Proposed inhibition mode of oryctin against α-chymotrypsin and leukocyte elastase-The crystal structures of OMTKY3 bound to α-chymotrypsin and leukocyte elastase have already been solved (PDB codes: 1CHO and 1PPF, respectively) (11, 12) (Fig. S5) . OMTKY3 binds α-chymotrypsin and leukocyte elastase through its reactive-site loop. The only sequentially similar segment between OMTKY3 and oryctin ( 15 ACTLE 19 in OMTKY3 and 11 LCTMD 15 in oryctin) is located in the active-site loop of OMTKY3 and the corresponding loop in oryctin. Since oryctin inhibits chymotrypsin-and subtilisin-like family proteases in a competitive manner (Fig. 5) , it should exhibit an inhibition mechanism similar to that of OMTKY3 by using the sequentially similar segment within the putative reactive-site loop. Based on the crystal structure of OMTKY3 bound to α-chymotrypsin and leukocyte elastase, we have constructed a binding model of oryctin to α-chymotrypsin and leukocyte elastase (Fig. 7A,B) . In this model, not only the reactive-site loop region but also the C-terminal α-helix uniquely found in oryctin is involved in the protease binding, which can cause a change in the orientation of the α-helix. This is consistent with the fact that the chemical shifts of most residues in the C-terminal α-helix are perturbed (> 0.02 ppm) by binding to the target proteases, although the chemical shift of the putative P1 residue, Met14, is not perturbed.
α-chymotrypsin and leukocyte elastase have large and small hydrophobic substrate-binding (S1) pockets, and thus prefer large and small hydrophobic residues at the P1 position, respectively (Fig. 7C,D) . This explains why oryctin with Met at the P1 position inhibits α-chymotrypsin (K i = 3.9 × 10 -10 M) more tightly than leukocyte elastase (K i = 1.2 × 10 -8 M). The large S1 pocket of α-chymotrypsin will fit to the large hydrophobic side chain of Met14 at the P1 position, but the small S1 pocket of leukocyte elastase will be too small to accommodate the Met side chain. In contrast, OMTKY3 with Leu at the P1 position can bind both α-chymotrypsin and leukocyte elastase very tightly, with K d values of 5.5 × 10 -12 M and 2.4 × 10 -11 M, respectively (11, 13) , because the small side chain of Leu at the P1 position can be accommodated in both the S1 pockets of α-chymotrypsin and leukocyte elastase. (Table S1 and Fig. S3B ). In fact, the phylogenetic analysis of all the Kazal-type inhibitors in Table S1 except oryctin can be performed without error using the Phylogeny.fr server (Fig. S6) (14) , but that with oryctin results in an error. (16) . This may imply that the N-terminal region of the Kazal-type inhibitors in higher animals played some additional role in the course of evolution. Possible biological roles of oryctin-Proteases and protease inhibitors are involved in the metabolism, immunity, and metamorphosis of insects (17, 18) . In particular, hemolymph proteases and protease inhibitors are involved in immune responses in insects, e.g., antimicrobial peptide induction, prophenoloxidase activation, hemolymph coagulation, and protection against virulence-related microbial proteases (17) . In the present study, we have shown that oryctin inhibits subtilisin-like serine proteases such as subtilisin Carlsberg and endopeptidase K. This suggests that oryctin is also involved in protection against microbial proteases. In the silkworm Bombyx mori, a protease inhibitor against fungal protease was isolated and is considered to play a role in innate immunity (19) . Although further investigation is required to reveal the in vivo function(s) of oryctin, the results obtained in this study indicate that oryctin is a novel and unique member of Kazal-type serine protease inhibitors. Despite the lack of sequence similarity, oryctin exhibits a similar linkage pattern of three disulfide bonds and an inhibition mechanism similar to that of the traditional Kazal-type inhibitors. (Fig. S5) . The chemical-shift-perturbed residues (> 0.02 ppm) are colored in magenta. The C α atom of the reactive site residue (P1 residue) is shown as a green sphere. The disulfide bonds are shown in yellow. The active-site triads of the α-chymotrypsin and leukocyte elastase are shown as cyan spheres. A unique additional α-helix at the C-terminus (α2) of oryctin would also be involved in the recognition of α-chymotrypsin and leukocyte elastase, and would contribute to the binding affinity. C,D. The crystal structure of the active-site loop of OMTKY3 (green) and the model of the corresponding loop of oryctin (blue) in the S1 pockets of α-chymotrypsin (C) and leukocyte elastase (D). Met 14 , the putative residue at the P1 position in oryctin, can fit into the S1 pocket of α-chymotrypsin, but it is too big to be accommodated by the S1 pocket of leukocyte elastase. 
